Hi,

I'm currently working on a project focused on designing a panel of methylation markers to detect brain-derived cfDNA in the plasma of multiple sclerosis (MS) patients. Our plan is to utilize the Illumina MiSeq platform for amplicon sequencing. The panel will undergo testing on both MS patients and healthy individuals.

To ensure that we effectively capture brain-derived cfDNA, I'm curious about the minimum required coverage necessary. Specifically, what level of coverage would be sufficient to detect brain-derived cfDNAs within the bulk of all extracted cfDNA from plasma?

Thank you in advance for your assistance.

Best regards,